share_log

SenesTech | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

SenesTech | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

SenesTech | S-8：员工福利计划证券登记
美股SEC公告 ·  08/06 16:07

Moomoo AI 已提取核心信息

SenesTech, Inc., a biotechnology company based in Delaware, has filed a Registration Statement with the U.S. Securities and Exchange Commission (SEC) on August 6, 2024, to register an additional 200,000 shares of common stock for issuance under its 2018 Equity Incentive Plan, as amended. This registration is in addition to the common stock previously registered under the plan through prior Registration Statements filed on various dates from 2018 to 2023. The company, which is classified as a non-accelerated filer and a smaller reporting company, incorporates by reference several documents including its Annual Report on Form 10-K for the year ended December 31, 2023, and its Quarterly Report for the quarter ended March 31, 2024. The filing includes the consent of its independent registered public accounting firm and legal counsel, and it is signed by key executives including President and CEO Joel L. Fruendt and CFO Thomas C. Chesterman.
SenesTech, Inc., a biotechnology company based in Delaware, has filed a Registration Statement with the U.S. Securities and Exchange Commission (SEC) on August 6, 2024, to register an additional 200,000 shares of common stock for issuance under its 2018 Equity Incentive Plan, as amended. This registration is in addition to the common stock previously registered under the plan through prior Registration Statements filed on various dates from 2018 to 2023. The company, which is classified as a non-accelerated filer and a smaller reporting company, incorporates by reference several documents including its Annual Report on Form 10-K for the year ended December 31, 2023, and its Quarterly Report for the quarter ended March 31, 2024. The filing includes the consent of its independent registered public accounting firm and legal counsel, and it is signed by key executives including President and CEO Joel L. Fruendt and CFO Thomas C. Chesterman.
生物技术公司SenesTech，总部位于特拉华州，于2024年8月6日向美国证券交易所（SEC）提交了一份注册声明，以在其2018年股权激励计划的基础上注册另外20万股普通股，经过修订。此注册除了之前从2018年到2023年在计划下已注册的普通股外，还包括几份文件，其中包括其截至2023年12月31日的10-k年度报告书以及其截至2024年3月31日的季度报告。该公司被归类为非加速调节申报人和小型报告公司。此申报包括独立注册会计师事务所和法律顾问的同意，并由总裁兼首席执行官Joel L. Fruendt 和首席财务官Thomas C. Chesterman签署。
生物技术公司SenesTech，总部位于特拉华州，于2024年8月6日向美国证券交易所（SEC）提交了一份注册声明，以在其2018年股权激励计划的基础上注册另外20万股普通股，经过修订。此注册除了之前从2018年到2023年在计划下已注册的普通股外，还包括几份文件，其中包括其截至2023年12月31日的10-k年度报告书以及其截至2024年3月31日的季度报告。该公司被归类为非加速调节申报人和小型报告公司。此申报包括独立注册会计师事务所和法律顾问的同意，并由总裁兼首席执行官Joel L. Fruendt 和首席财务官Thomas C. Chesterman签署。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间